JP2024538602A - インターロイキン－１活性の阻害剤としての新規の置換スルホニル尿素化合物 - Google Patents

インターロイキン－１活性の阻害剤としての新規の置換スルホニル尿素化合物 Download PDF

Info

Publication number
JP2024538602A
JP2024538602A JP2024519269A JP2024519269A JP2024538602A JP 2024538602 A JP2024538602 A JP 2024538602A JP 2024519269 A JP2024519269 A JP 2024519269A JP 2024519269 A JP2024519269 A JP 2024519269A JP 2024538602 A JP2024538602 A JP 2024538602A
Authority
JP
Japan
Prior art keywords
mmol
compound
mixture
occurrence
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024519269A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024538602A5 (enExample
Inventor
ホンジャン ジャン
ピン チェン
フェイ ジャン
ペイフワ スン
Original Assignee
ビバ スター バイオサイエンシズ （スージョウ） カンパニー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ビバ スター バイオサイエンシズ （スージョウ） カンパニー リミテッド filed Critical ビバ スター バイオサイエンシズ （スージョウ） カンパニー リミテッド
Publication of JP2024538602A publication Critical patent/JP2024538602A/ja
Publication of JP2024538602A5 publication Critical patent/JP2024538602A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2024519269A 2021-09-29 2022-09-27 インターロイキン－１活性の阻害剤としての新規の置換スルホニル尿素化合物 Pending JP2024538602A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2021/121548 2021-09-29
CN2021121548 2021-09-29
PCT/US2022/077120 WO2023056264A1 (en) 2021-09-29 2022-09-27 Novel substituted sulfonylurea compounds as inhibitors of interleukin-1 activity

Publications (2)

Publication Number Publication Date
JP2024538602A true JP2024538602A (ja) 2024-10-23
JP2024538602A5 JP2024538602A5 (enExample) 2025-09-19

Family

ID=84329267

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024519269A Pending JP2024538602A (ja) 2021-09-29 2022-09-27 インターロイキン－１活性の阻害剤としての新規の置換スルホニル尿素化合物

Country Status (10)

Country Link
US (1) US20240400561A1 (enExample)
EP (1) EP4408843A1 (enExample)
JP (1) JP2024538602A (enExample)
KR (1) KR20240089127A (enExample)
CN (1) CN118251393A (enExample)
AU (1) AU2022356377A1 (enExample)
CA (1) CA3233673A1 (enExample)
IL (1) IL311784A (enExample)
MX (1) MX2024003948A (enExample)
WO (1) WO2023056264A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024538602A (ja) * 2021-09-29 2024-10-23 ビバ スター バイオサイエンシズ （スージョウ） カンパニー リミテッド インターロイキン－１活性の阻害剤としての新規の置換スルホニル尿素化合物
TW202545527A (zh) 2024-01-16 2025-12-01 英商諾得瑟拉公司 Ｎｌｒｐ３及ｇｌｐ－１ａ組合療法

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019008029A1 (en) * 2017-07-07 2019-01-10 Inflazome Limited SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3
WO2019034692A1 (en) * 2017-08-15 2019-02-21 Inflazome Limited SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3
WO2020035466A1 (en) * 2018-08-15 2020-02-20 Inflazome Limited Novel sulfoneurea compounds
WO2020035465A1 (en) * 2017-08-15 2020-02-20 Inflazome Limited Novel sulfoneurea compounds
JP2020526589A (ja) * 2017-07-07 2020-08-31 インフレイゾーム リミテッド 新規なスルホンアミドカルボキサミド化合物
JP2020531435A (ja) * 2017-08-15 2020-11-05 インフレイゾーム リミテッド 新規なスルホンアミドカルボキサミド化合物
JP2021502364A (ja) * 2017-11-09 2021-01-28 インフレイゾーム リミテッド 新規なスルホンアミドカルボキサミド化合物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024538602A (ja) * 2021-09-29 2024-10-23 ビバ スター バイオサイエンシズ （スージョウ） カンパニー リミテッド インターロイキン－１活性の阻害剤としての新規の置換スルホニル尿素化合物

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019008029A1 (en) * 2017-07-07 2019-01-10 Inflazome Limited SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3
JP2020526589A (ja) * 2017-07-07 2020-08-31 インフレイゾーム リミテッド 新規なスルホンアミドカルボキサミド化合物
WO2019034692A1 (en) * 2017-08-15 2019-02-21 Inflazome Limited SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3
WO2020035465A1 (en) * 2017-08-15 2020-02-20 Inflazome Limited Novel sulfoneurea compounds
JP2020531435A (ja) * 2017-08-15 2020-11-05 インフレイゾーム リミテッド 新規なスルホンアミドカルボキサミド化合物
JP2021502364A (ja) * 2017-11-09 2021-01-28 インフレイゾーム リミテッド 新規なスルホンアミドカルボキサミド化合物
WO2020035466A1 (en) * 2018-08-15 2020-02-20 Inflazome Limited Novel sulfoneurea compounds

Also Published As

Publication number Publication date
KR20240089127A (ko) 2024-06-20
CA3233673A1 (en) 2023-04-06
US20240400561A1 (en) 2024-12-05
MX2024003948A (es) 2024-06-28
EP4408843A1 (en) 2024-08-07
AU2022356377A1 (en) 2024-04-11
IL311784A (en) 2024-05-01
CN118251393A (zh) 2024-06-25
WO2023056264A1 (en) 2023-04-06

Similar Documents

Publication Publication Date Title
KR101701663B1 (ko) 3-치환된 피라졸 및 dlk 억제제로서의 용도
EP4333899A1 (en) Compounds for targeting degradation of bruton's tyrosine kinase
JP2021107414A (ja) コロニー刺激因子−１受容体（ｃｓｆ−１ｒ）阻害剤
JP7163379B2 (ja) Ｉｌ－１７調節剤としてのスピロ環インドリン
JP2021500345A (ja) ムスカリン性アセチルコリン受容体ｍ４のアンタゴニスト
CA3047336A1 (en) Chemical compounds as inhibitors of interleukin-1 activity
KR20210019489A (ko) B형 간염 캡시드 조립 조절제
EP4129996A1 (en) Novel aminopyrimidine egfr inhibitor
CA2916468A1 (en) Heteroaryl compounds useful as inhibitors of sumo activating enzyme
JP2024517769A (ja) Ｌｐａアンタゴニストとしての新規トリアゾール－ピリジン置換ピロリジニル及びテトラヒドロ－２ｈ－ピラニル酢酸化合物
CA3180717A1 (en) Condensed substituted hydropyrroles as antagonists of the muscarinic acetylcholine receptor m4
WO2022187266A1 (en) Novel substituted bicycli aza-heterocycles as sos1 inhibitors
CA3241298A1 (en) Antagonists of the muscarinic acetylcholine receptor m4
KR20230124608A (ko) 무스카린성 아세틸콜린 수용체 m4의 길항제
CN119487006A (zh) 作为pge2受体拮抗剂的酰胺化合物
AU2022356377A1 (en) Novel substituted sulfonylurea compounds as inhibitors of interleukin-1 activity
AU2014234908A1 (en) N-(2-cyano heterocyclyl)pyrazolo pyridones as Janus kinase inhibitors
KR20150056550A (ko) 키나제 억제제로서의 디히드로피롤리디노-피리미딘
US12338255B2 (en) Bicyclic substituted sulfonylurea compounds as inhibitors of interleukin-1 activity
HK40107097A (en) Novel substituted sulfonylurea compounds as inhibitors of interleukin-1 activity
HK40116219A (en) Novel bicyclic substituted sulfonylurea compounds as inhibitors of interleukin-1 activity
HK40102702A (en) Novel triazole-pyridine substituted pyrrolidinyl and tetrahydro-2h-pyranyl acetic acid compounds as lpa antagonists
EA052733B1 (ru) Ингибиторы nlrp3

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250910

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250910

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260518

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260526

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20260624

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20260804